| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2003;108:166.)
© 2003 American Heart Association, Inc.
Clinical Investigation and Reports |
From the Henry Ford Heart and Vascular Institute (J.J.C.), Detroit, Mich; Merck Research Laboratory (C.T.), Rahway, NJ; National Heart, Lung, and Blood Institute (T.A.M.), Bethesda, Md; University of Washington (B.M.P.), Seattle, Wash; University of Pittsburgh (L.H.K., K.S.-T.), Pittsburgh, Pa; Johns Hopkins University (P.H.M.C.), Baltimore, Md; Brigham and Womens Hospital (J.F.P.), Boston, Mass; Wake Forest University (D.M.H.), Winston-Salem, NC; University of Maryland (T.R.P.), Baltimore, Md; and University of Vermont (M.C.), Burlington, Vt.
Correspondence to Mary Cushman, MD, MSc, Department of Medicine, University of Vermont, 208 S Park Dr, Suite 2, Colchester, VT 05446. E-mail mary.cushman{at}uvm.edu
Received September 25, 2002; revision received April 17, 2003; accepted April 18, 2003.
| Abstract |
|---|
|
|
|---|
Methods and Results We studied 5417 participants aged 65 years or older without preexisting stroke or chronic atrial fibrillation who were participants in the Cardiovascular Health Study. The hazard ratio of incident ischemic stroke was estimated by Cox proportional hazards regression. During 10.2 years of follow-up, 469 incident ischemic strokes occurred. The adjusted hazard ratios for ischemic stroke in the 2nd to 4th quartiles of baseline CRP, relative to the 1st quartile, were 1.19 (95% CI 0.92 to 1.53), 1.05 (95% CI 0.81 to 1.37), and 1.60 (95% CI 1.23 to 2.08), respectively. With additional adjustment for carotid IMT, there was little confounding. The association of CRP with stroke was significantly different depending on IMT (P<0.02), with no association of CRP with stroke among those in the lowest IMT tertile and a significant association among those with higher levels of IMT.
Conclusions We conclude that elevated CRP is a risk factor for ischemic stroke, independent of atherosclerosis severity as measured by carotid IMT. The association of CRP with stroke is more apparent in the presence of a higher carotid IMT. CRP and carotid IMT may each be independent integrals in determining the risk of ischemic stroke.
Key Words: inflammation atherosclerosis carotid arteries stroke risk factors
| Introduction |
|---|
|
|
|---|
Inflammation mediates a key role in the pathogenesis of atherosclerosis.9,10 Various cytokines, growth factors, and inflammatory cells are abundant in atheromatous plaques.9,10 The atherosclerotic vessel wall is the source of soluble adhesion molecules that mark inflammation.11,12 Endarterectomy specimens from symptomatic patients compared with asymptomatic patients and those in areas with more extensive plaques have higher expression of adhesion molecules.13 Thus, the extent of inflammation may reflect in part the propensity of atherosclerotic lesions to lead to clinical disease.
It appears that among inflammation-sensitive proteins studied to date in relation to cardiovascular disease risk, higher CRP concentration is most consistently and strongly related to risk.14,15 Higher CRP might be a marker of destabilizing plaques, and CRP itself might also participate in plaque destabilization.16 It has been proposed that CRP reflects the overall inflammatory burden of atherosclerotic disease.17 However, there is also evidence for possible direct roles of CRP in the pathogenesis of atherosclerosis, such as induction of endothelial cell adhesion molecules,18 opsonization of native LDL to form foam cells,19 induction of monocyte tissue factor production,20 and recruitment of monocytes by receptor-mediated chemotaxis.21
We hypothesize here that CRP is a risk factor for stroke independent of carotid IMT and, because it might be a marker of plaque severity and instability, that CRP would be more strongly related to stroke among those with higher carotid IMT. We investigated the hypothesis in adults who were 65 years of age or older without preexisting stroke and who were participants in the Cardiovascular Health Study (CHS).
| Methods |
|---|
|
|
|---|
All participants underwent baseline clinical examinations, which included medical history, physical examination, carotid ultrasound, ECG, and ankle-brachial blood pressure index.23 The diagnoses of diabetes mellitus and impaired fasting glucose were based on American Diabetes Association criteria.24 Blood was drawn in the morning after an overnight fast.25 Samples were promptly centrifuged at 3000g for 10 minutes at 4°C. Aliquots of plasma were stored in a central laboratory at -70°C. In 1997, CRP was measured in all stored baseline plasma samples by a high-sensitivity immunoassay, with an interassay coefficient of variation of 6.25%.26
The carotid arteries were evaluated at baseline with high-resolution B-mode ultrasonography (model SSA-270A; Toshiba America Medical Systems). The maximum IMT of the common carotid artery and of the internal carotid artery was defined as the mean of multiple measures of the maximum IMT of the near and far wall on both the left and right sides. Methods of measurement and quality control have been published previously.27 A composite measure that combined the maximum common carotid artery IMT and maximum internal IMT was obtained by averaging these 2 measurements after standardization (subtraction of the mean and division by the standard deviation for the measurement).28
The method of ascertainment and classification of incident stroke has been reported previously.29 Participants were examined annually at each clinical site. In addition, telephone interviews were alternated with clinic visits so that contacts occurred every 6 months. Follow-up was complete through June 30, 2000. Incident stroke was ascertained by self-report or from the Health Care Financing Administration hospitalized patient database of International Classification of Diseases, 9th Revision (ICD-9) codes. For confirmation and classification of stroke type, hospital records, including cranial computed tomography and cerebral magnetic resonance images, were reviewed by a committee that included neurologists and a neuroradiologist. Only ischemic cerebral infarction was included as stroke in this analysis. Those participants who suffered primarily from hemorrhagic stroke were not included in this analysis.
Statistical Analysis
All analyses were performed with SAS version 6.12 software. Differences between CRP medians were tested with the Kruskal-Wallis test for factors with more than 2 groups. Differences in means of risk factor levels between the stroke group and the no-stroke group were tested with t tests. For variables with skewed distributions, the Wilcoxon rank-sum test was used to test for differences in medians. The
2 test was used to assess associations among categorical variables. To equalize the power across quartiles, quartiles were defined on the basis of the distribution of CRP among those with events.
Cox proportional hazards regression was used to calculate hazard ratios (HRs) of stroke for elevated CRP in multivariate models that included adjustment for age, gender, race, diabetes status (normal, fasting glucose intolerance, and diabetes mellitus), hypertension, systolic blood pressure, smoking status (never, current, or past), and total cholesterol. Factors not associated with stroke were not included in these models. The interaction between CRP and carotid IMT as continuous variables and as categorical variables was tested. A probability value of less than 0.05 was considered statistically significant.
| Results |
|---|
|
|
|---|
The baseline characteristics of the study cohort are shown in Table 1. Those with incident stroke were more likely to have baseline hypertension, diabetes or impaired fasting glucose, higher total cholesterol, and higher systolic and diastolic blood pressure. Compared with the control group, the stroke group had higher internal carotid thickness and higher common carotid thickness (both P<0.001). Median baseline CRP was significantly higher in the stroke group than in the control group (P<0.01).
|
CRP concentration was closely correlated with carotid IMT measures. For each 1 SD higher of common or internal carotid IMT, CRP was 0.37 and 0.40 mg/L higher, respectively (P<0.001 for Spearman correlation). Although they were highly statistically significant for both men and women, the correlations were larger among men. For example, for each 1 SD higher of internal carotid IMT, CRP was 0.60 mg/L higher for men and 0.26 mg/L higher for women.
In the first to fourth quartiles of baseline CRP, the respective stroke incidence rates were 8.2, 10.4, 9.6, and 14.8 strokes per 1000 person-years. In Table 2, multivariate analysis of the HR of stroke for CRP categories was based on a model that adjusted for age, gender, race, hypertension, diabetes, systolic blood pressure, total cholesterol, and smoking status. Compared with the first quartile of CRP, the adjusted HRs of stroke for the second, third, and fourth quartiles were 1.19 (95% CI 0.92 to 1.53), 1.05 (95% CI 0.81 to 1.37), and 1.60 (95% CI 1.23 to 2.08), respectively. With additional adjustment for internal carotid IMT, common carotid IMT, or combined carotid IMT, there was little confounding, with the HR comparing the fourth to the first quartile being 1.5 for each adjusted model (Table 2).
|
In gender-stratified analyses, the unadjusted risk of stroke in the fourth compared with the first quartile of CRP was 2.21 (95% CI 1.50 to 3.25) in men and 1.64 (95% CI 1.17 to 2.31) in women. This difference was not statistically significant (P for interaction of CRP and sex, 0.07). In both men and women, the risk was attenuated with adjustment for other risk factors (OR 1.88 [95% CI 1.25 to 2.81] and 1.38 [95% CI 0.97 to 1.97], respectively). With further adjustment for combined carotid IMT, these ORs changed trivially (1.69 [95% CI 1.13 to 2.54] for men; 1.33 [95% CI 0.93 to 1.91] for women). In this final model, the interaction term P value for sex and CRP was 0.36.
As reported previously, the risk of ischemic stroke was significantly increased with increasing common, internal, and combined carotid IMT (data not shown).2 To address whether the CRP-related stroke risk differed within categories of IMT, we expressed the HR of stroke per interquartile range (2.38 mg/L) higher CRP. Overall, the adjusted HR of stroke per interquartile range of CRP was 1.05 (1.02 to 1.07). With stratification by tertiles of IMT, the interquartile range HRs are shown in Table 3. CRP was significantly associated with stroke risk in the second and third tertiles of each IMT measurement. However, among those in the first tertile of IMT, the association of CRP with stroke risk was weak or not present. As an example, considering combined carotid IMT, the risk of stroke was increased 7% for each interquartile range of higher CRP concentration among those in the second or third tertile of combined IMT. The risk of stroke was increased only 3% per interquartile range of higher CRP among those in the first tertile of combined carotid IMT (P=0.21). The interaction term of CRP and IMT to predict stroke was statistically significant, which supports multiplicative interaction (P=0.002, 0.02, and 0.003 for internal, common, and combined carotid IMT, respectively). The overall results were unaltered if women were excluded from the analyses.
|
| Discussion |
|---|
|
|
|---|
We confirm here that CRP and IMT are closely associated; the higher the CRP, the greater the carotid atherosclerosis as measured by carotid IMT, as also reported by others.5,6 The atherosclerotic vessel wall is a likely source of measurable systemic inflammation. Therefore, elevated CRP in part reflects the burden of atherosclerosis. It appears, however, that CRP may not simply represent the extent of atherosclerosis severity, because CRP remained an independent risk factor for ischemic stroke even when atherosclerosis was advanced, as defined by IMT. A recent report by Park et al30 demonstrated that coronary calcium score and CRP provided independent and complementary prediction of cardiovascular events. Further study on the interrelations of inflammation markers and subclinical atherosclerosis in relation to clinical outcomes is required.
In the present study, the association of CRP with stroke was significant not only in the highest tertile of IMT but also in the second tertile of IMT. In fact, the stroke risks for higher CRP within the second and third tertiles of IMT were comparable. Several hypotheses requiring further evaluation may be raised based on these findings. The CRP concentration might be related to the composition of the carotid atherosclerotic plaque, such that higher CRP is associated with a more active or unstable plaque, with greater propensity to stroke.5,16 Therefore, CRP-associated stroke risk is more significant when there is greater measurable plaque burden that is subject to rupture. It is possible that an elevated CRP is causally related to onset of stroke, primarily among those with atherosclerosis. Proposed biological activities of CRP within plaques, such as complement activation,31 induction of leukocyte chemotaxis21 and adhesion molecules,18 opsonization of LDL,19 and induction of monocyte tissue factor production,20 would support these hypotheses.
Strengths of the present study include the prospectively collected data from a large sample of older, community-based individuals and the availability of carefully performed measures of subclinical atherosclerosis before the onset of stroke. The limitations include the relatively low incidence of ischemic stroke in this healthy elderly cohort. Although this lower incidence is likely due to selection and survival of a healthier cohort,32 one would not expect these biases to affect prospective associations within the cohort in important ways. However, these findings should be further explored in studies with higher prevalences of carotid disease and stroke risk factors, including other population-based cohorts. Other limitations include the determination of IMT and CRP by a single measure, which could result in imprecision or residual confounding due to measurement error. We believe this would bias our findings toward the null hypothesis, yielding underestimates of the actual risk associated with these measures.
We conclude that elevated CRP is related to the future occurrence of ischemic stroke in this elderly cohort, an association that is largely independent of atherosclerosis severity as measured by carotid IMT. The association of CRP with stroke was less apparent among those with less advanced compared with more advanced carotid atherosclerosis. Although CRP and carotid IMT are closely correlated, each factor may be an independent integral in the risk of ischemic stroke. There is a trend to suggest that the association of CRP and stroke might be stronger in men than in women. These findings should be further explored both in the laboratory and in ongoing observational and interventional studies.
| Acknowledgments |
|---|
| Footnotes |
|---|
| References |
|---|
|
|
|---|
2. OLeary DH, Polak JF, Kronmal RA, et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults: Cardiovascular Health Study Collaborative Research Group. N Engl J Med. 1999; 340: 1422.
3. Gussekloo J, Schaap MCL, Frolich M, et al. C-reactive protein is a strong but nonspecific risk factor of fatal stroke in elderly persons. Arterioscler Thromb Vasc Biol. 2000; 20: 10471051.
4. Rost NS, Wolf PA, Kase CS, et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke. 2001; 32: 25752579.
5. Blackburn R, Giral P, Bruckert E, et al. Elevated C-reactive protein constitutes an independent predictor of advanced carotid plaques in dyslipidemic subjects. Arterioscler Thromb Vasc Biol. 2001; 21: 19621968.
6. Wang TJ, Nam BH, Wilson PW, et al. Association of C-reactive protein with carotid atherosclerosis in men and women: the Framingham Heart Study. Arterioscler Thromb Vasc Biol. 2002; 22: 16621667.
7. Tracy RP, Psaty BM, Macy E, et al. Lifetime smoking exposure affects the association of C-reactive protein with cardiovascular disease risk factors and subclinical disease in healthy elderly subjects. Arterioscler Thromb Vasc Biol. 1997; 17: 21672176.
8. Folsom AR, Pankow JS, Tracy RP, et al. Association of C-reactive protein with markers of prevalent atherosclerotic disease. Am J Cardiol. 2001; 88: 112117.[CrossRef][Medline] [Order article via Infotrieve]
9. Jonasson L, Holm J, Skalli O, et al. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis. 1986; 6: 131138.
10. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999; 340: 115126.
11. De Caterina R, Basta G, Lazzerini G, et al. Soluble vascular cell adhesion molecule-1 as a biohumoral correlate of atherosclerosis. Arterioscler Thromb Vasc Biol. 1997; 17: 26462654.
12. Hwang SJ, Ballantyne CM, Sharrett AR, et al. Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 1997; 96: 42194225.
13. DeGraba TJ, Siren AL, Penix L, et al. Increased endothelial expression of intercellular adhesion molecule-1 in symptomatic versus asymptomatic human carotid atherosclerotic plaque. Stroke. 1998; 29: 14051410.
14. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000; 342: 836843.
15. Ridker PM. High-sensitivity C-reactive protein: potential adjunct to global risk assessment in primary prevention of cardiovascular disease. Circulation. 2001; 103: 18131818.
16. Burke AP, Tracy RP, Kolodgie F, et al. Elevated C-reactive protein values and atherosclerosis in sudden coronary death: association with different pathologies. Circulation. 2002; 105: 20192023.
17. Tracy RP, Lemaitre RN, Psaty BM, et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly: results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol. 1997; 17: 11211127.
18. Pasceri V, Willerson JT, Yeh ETH. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000; 102: 21652168.
19. Zwaka TP, Hombach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation. 2001; 103: 11941197.
20. Cermak J, Key N, Bach R, et al. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood. 1993; 82: 513520.
21. Torzewski M, Rist C, Mortensen RF, et al. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler Thromb Vasc Biol. 2000; 20: 20942099.
22. Fried LP, Borhani NO, Enright P, et al. The Cardiovascular Health Study: design and rationale. Ann Epidemiol. 1991; 1: 263276.[Medline] [Order article via Infotrieve]
23. Kuller L, Borhani N, Furberg K, et al. Prevalence of subclinical atherosclerosis and cardiovascular disease and association with risk factors in the Cardiovascular Health Study. Am J Epidemiol. 1994; 139: 11641179.
24. The Expert Committee on Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on Diagnosis and Classification of Diabetes Mellitus. Diabetes Care. 1997; 20: 11831197.[Medline] [Order article via Infotrieve]
25. Cushman M, Cornell ES, Howard PR, et al. Laboratory methods and quality assurance in the Cardiovascular Health Study. Clin Chem. 1995; 42: 264270.
26. Macy EM, Hayes TE, Tracy RP. Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem. 1997; 43: 5258.
27. OLeary DH, Polak JF, Wolfson SK, et al. Use of sonography to evaluate carotid atherosclerosis in the elderly: the Cardiovascular Health Study. Stroke. 1991; 22: 11551163.
28. OLeary DH, Polak JF, Kronmal RA, et al. Thickening of the carotid wall: a marker for atherosclerosis in the elderly? Cardiovascular Health Study Collaborative Research Group. Stroke. 1996; 27: 224231.
29. Psaty BM, Kuller LH, Bild D, et al. Methods of assessing prevalent cardiovascular disease in the Cardiovascular Health Study. Ann Epidemiol. 1995; 5: 270277.[CrossRef][Medline] [Order article via Infotrieve]
30. Park R, Detrano R, Xiang M, et al. Combined use of computed tomography coronary calcium scores and C-reactive protein levels in predicting cardiovascular events in nondiabetic individuals. Circulation. 2002; 106: 20732077.
31. Bhakdi S, Torzewski M, Klouche M, et al. Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation. Arterioscler Thromb Vasc Biol. 1999; 19: 23482354.
32. Tell GS, Fried LP, Hermanson B, et al. Recruitment of adults 65 years and older as participants in the Cardiovascular Health Study. Ann Epidemiol. 1993; 3: 358366.[Medline] [Order article via Infotrieve]
This article has been cited by other articles:
![]() |
C. B. Wright, Y. Moon, M. C. Paik, T. R. Brown, L. Rabbani, M. Yoshita, C. DeCarli, R. Sacco, and M. S.V. Elkind Inflammatory Biomarkers of Vascular Risk as Correlates of Leukoariosis Stroke, November 1, 2009; 40(11): 3466 - 3471. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.S.V. Elkind, J. M. Luna, Y. P. Moon, K. M. Liu, S. L. Spitalnik, M. C. Paik, and R. L. Sacco High-sensitivity C-reactive protein predicts mortality but not stroke: The Northern Manhattan Study Neurology, October 20, 2009; 73(16): 1300 - 1307. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Helfand, D. I. Buckley, M. Freeman, R. Fu, K. Rogers, C. Fleming, and L. L. Humphrey Emerging Risk Factors for Coronary Heart Disease: A Summary of Systematic Reviews Conducted for the U.S. Preventive Services Task Force Ann Intern Med, October 6, 2009; 151(7): 496 - 507. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. S. Jenny, A. M. Arnold, L. H. Kuller, R. P. Tracy, and B. M. Psaty Associations of Pentraxin 3 With Cardiovascular Disease and All-Cause Death: The Cardiovascular Health Study Arterioscler Thromb Vasc Biol, April 1, 2009; 29(4): 594 - 599. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Salvarani, C. D. Bella, L. Cimino, P. Macchioni, D. Formisano, G. Bajocchi, N. Pipitone, M. G. Catanoso, G. Restuccia, A. Ghinoi, et al. Risk factors for severe cranial ischaemic events in an Italian population-based cohort of patients with giant cell arteritis Rheumatology, March 1, 2009; 48(3): 250 - 253. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. D. Sturgeon, A. R. Folsom, W.T. Longstreth Jr, E. Shahar, W. D. Rosamond, and M. Cushman Hemostatic and Inflammatory Risk Factors for Intracerebral Hemorrhage in a Pooled Cohort Stroke, August 1, 2008; 39(8): 2268 - 2273. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Fornage, Y. A. Chiang, E. S. O'Meara, B. M. Psaty, A. P. Reiner, D. S. Siscovick, R. P. Tracy, and W.T. Longstreth Jr Biomarkers of Inflammation and MRI-Defined Small Vessel Disease of the Brain: The Cardiovascular Health Study Stroke, July 1, 2008; 39(7): 1952 - 1959. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C. Larsson, S. Mannisto, M. J. Virtanen, J. Kontto, D. Albanes, and J. Virtamo Coffee and Tea Consumption and Risk of Stroke Subtypes in Male Smokers Stroke, June 1, 2008; 39(6): 1681 - 1687. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Matheson, M. S. Player, A. G. Mainous III, D. E. King, and C. J. Everett The Association Between Hay Fever and Stroke in a Cohort of Middle Aged and Elderly Adults J Am Board Fam Med, May 1, 2008; 21(3): 179 - 183. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. A. Wasserman, A. R. Sharrett, S. Lai, A. S. Gomes, M. Cushman, A. R. Folsom, D. E. Bild, R. A. Kronmal, S. Sinha, and D. A. Bluemke Risk Factor Associations With the Presence of a Lipid Core in Carotid Plaque of Asymptomatic Individuals Using High-Resolution MRI: The Multi-Ethnic Study of Atherosclerosis (MESA) Stroke, February 1, 2008; 39(2): 329 - 335. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kinlay, G. G. Schwartz, A. G. Olsson, N. Rifai, M. Szarek, D. D. Waters, P. Libby, P. Ganz, and for the Myocardial Ischemia Reduction with Aggress Inflammation, Statin Therapy, and Risk of Stroke After an Acute Coronary Syndrome in the MIRACL Study Arterioscler Thromb Vasc Biol, January 1, 2008; 28(1): 142 - 147. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Sander, C. Schulze Horn, C. Briesenick, and D. Sander High-Sensitivity C-Reactive Protein Is Independently Associated With Early Carotid Artery Progression in Women But Not in Men: The INVADE Study Stroke, November 1, 2007; 38(11): 2881 - 2886. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Femia, M. Kozakova, M. Nannipieri, C. Gonzales-Villalpando, M. P. Stern, S. M. Haffner, and E. Ferrannini Carotid Intima-Media Thickness in Confirmed Prehypertensive Subjects: Predictors and Progression Arterioscler Thromb Vasc Biol, October 1, 2007; 27(10): 2244 - 2249. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Reitz, K. Berger, M. P.M. de Maat, M. Stoll, F. Friedrichs, I. Kardys, J. C.M. Witteman, and M. M.B. Breteler CRP Gene Haplotypes, Serum CRP, and Cerebral Small-Vessel Disease: The Rotterdam Scan Study and the MEMO Study Stroke, August 1, 2007; 38(8): 2356 - 2359. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. W. Lorenz, P. Karbstein, H. S. Markus, and M. Sitzer High-Sensitivity C-Reactive Protein Is Not Associated With Carotid Intima-Media Progression: The Carotid Atherosclerosis Progression Study Stroke, June 1, 2007; 38(6): 1774 - 1779. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. M. Ridker C-Reactive Protein and the Prediction of Cardiovascular Events Among Those at Intermediate Risk: Moving an Inflammatory Hypothesis Toward Consensus J. Am. Coll. Cardiol., May 29, 2007; 49(21): 2129 - 2138. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Ishikawa, Y. Tamura, S. Hoshide, K. Eguchi, S. Ishikawa, K. Shimada, and K. Kario Low-Grade Inflammation Is a Risk Factor for Clinical Stroke Events in Addition to Silent Cerebral Infarcts in Japanese Older Hypertensives: The Jichi Medical School ABPM Study, Wave 1 Stroke, March 1, 2007; 38(3): 911 - 917. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. Lange, C. S. Carlson, L. A. Hindorff, E. M. Lange, J. Walston, J. P. Durda, M. Cushman, J. C. Bis, D. Zeng, D. Lin, et al. Association of Polymorphisms in the CRP Gene With Circulating C-Reactive Protein Levels and Cardiovascular Events JAMA, December 13, 2006; 296(22): 2703 - 2711. [Abstract] [Full Text] [PDF] |
||||
![]() |
Q. Wang, S. C. Hunt, Q. Xu, Y. E. Chen, M. A. Province, J. H. Eckfeldt, J. S. Pankow, and Q. Song Association study of CRP gene polymorphisms with serum CRP level and cardiovascular risk in the NHLBI Family Heart Study Am J Physiol Heart Circ Physiol, December 1, 2006; 291(6): H2752 - H2757. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Schmidt, H. Schmidt, M. Pichler, C. Enzinger, K. Petrovic, K. Niederkorn, S. Horner, S. Ropele, N. Watzinger, M. Schumacher, et al. C-Reactive Protein, Carotid Atherosclerosis, and Cerebral Small-Vessel Disease: Results of the Austrian Stroke Prevention Study Stroke, December 1, 2006; 37(12): 2910 - 2916. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. A. Lakka, T. Rankinen, T. Rice, A. S. Leon, D. C. Rao, J. S. Skinner, and C. Bouchard Quantitative trait locus on chromosome 20q13 for plasma levels of C-reactive protein in healthy whites: the HERITAGE Family Study Physiol Genomics, October 11, 2006; 27(2): 103 - 107. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Bos, C. M. A. Schipper, P. J. Koudstaal, J. C.M. Witteman, A. Hofman, and M. M.B. Breteler High Serum C-Reactive Protein Level Is Not an Independent Predictor for Stroke: The Rotterdam Study Circulation, October 10, 2006; 114(15): 1591 - 1598. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Dziedzic Systemic inflammatory markers and risk of dementia. American Journal of Alzheimer's Disease and Other Dementias, August 1, 2006; 21(4): 258 - 262. [Abstract] [PDF] |
||||
![]() |
J. R. Crouse III Thematic review series: Patient-Oriented Research. Imaging atherosclerosis: state of the art J. Lipid Res., August 1, 2006; 47(8): 1677 - 1699. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Tanne, M. Benderly, U. Goldbourt, M. Haim, A. Tenenbaum, E. Z. Fisman, Z. Matas, Y. Adler, R. Zimmlichman, and S. Behar C-Reactive Protein as a Predictor of Incident Ischemic Stroke Among Patients With Preexisting Cardiovascular Disease Stroke, July 1, 2006; 37(7): 1720 - 1724. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. K. Ikram, F. J. de Jong, M. J. Bos, J. R. Vingerling, A. Hofman, P. J. Koudstaal, P. T.V.M. de Jong, and M.M.B. Breteler Retinal vessel diameters and risk of stroke: The Rotterdam Study Neurology, May 9, 2006; 66(9): 1339 - 1343. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Hermann and F. Ruschitzka Novel anti-inflammatory drugs in hypertension Nephrol. Dial. Transplant., April 1, 2006; 21(4): 859 - 864. [Full Text] [PDF] |
||||
![]() |
A. Khera, J. A. de Lemos, R. M. Peshock, H. S. Lo, H. G. Stanek, S. A. Murphy, F. H. Wians Jr, S. M. Grundy, and D. K. McGuire Relationship Between C-Reactive Protein and Subclinical Atherosclerosis: The Dallas Heart Study Circulation, January 3, 2006; 113(1): 38 - 43. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Wakugawa, Y. Kiyohara, Y. Tanizaki, M. Kubo, T. Ninomiya, J. Hata, Y. Doi, K. Okubo, Y. Oishi, K. Shikata, et al. C-Reactive Protein and Risk of First-Ever Ischemic and Hemorrhagic Stroke in a General Japanese Population: The Hisayama Study Stroke, January 1, 2006; 37(1): 27 - 32. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Ballantyne, R. C. Hoogeveen, H. Bang, J. Coresh, A. R. Folsom, L. E. Chambless, M. Myerson, K. K. Wu, A. R. Sharrett, and E. Boerwinkle Lipoprotein-Associated Phospholipase A2, High-Sensitivity C-Reactive Protein, and Risk for Incident Ischemic Stroke in Middle-aged Men and Women in the Atherosclerosis Risk in Communities (ARIC) Study Arch Intern Med, November 28, 2005; 165(21): 2479 - 2484. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Minoguchi, T. Yokoe, T. Tazaki, H. Minoguchi, A. Tanaka, N. Oda, S. Okada, S. Ohta, H. Naito, and M. Adachi Increased Carotid Intima-Media Thickness and Serum Inflammatory Markers in Obstructive Sleep Apnea Am. J. Respir. Crit. Care Med., September 1, 2005; 172(5): 625 - 630. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. P. Grocott, W. D. White, R. W. Morris, M. V. Podgoreanu, J. P. Mathew, D. M. Nielsen, D. A. Schwinn, M. F. Newman, and for the Perioperative Genetics and Safety Outcomes Genetic Polymorphisms and the Risk of Stroke After Cardiac Surgery Stroke, September 1, 2005; 36(9): 1854 - 1858. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Cushman, A. M. Arnold, B. M. Psaty, T. A. Manolio, L. H. Kuller, G. L. Burke, J. F. Polak, and R. P. Tracy C-Reactive Protein and the 10-Year Incidence of Coronary Heart Disease in Older Men and Women: The Cardiovascular Health Study Circulation, July 5, 2005; 112(1): 25 - 31. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Di Napoli, M. Schwaninger, R. Cappelli, E. Ceccarelli, G. Di Gianfilippo, C. Donati, H. C.A. Emsley, S. Forconi, S. J. Hopkins, L. Masotti, et al. Evaluation of C-Reactive Protein Measurement for Assessing the Risk and Prognosis in Ischemic Stroke: A Statement for Health Care Professionals From the CRP Pooling Project Members Stroke, June 1, 2005; 36(6): 1316 - 1329. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. B. Kritchevsky, M. Cesari, and M. Pahor Inflammatory markers and cardiovascular health in older adults Cardiovasc Res, May 1, 2005; 66(2): 265 - 275. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. J. Nicklas, T. You, and M. Pahor Behavioural treatments for chronic systemic inflammation: effects of dietary weight loss and exercise training Can. Med. Assoc. J., April 26, 2005; 172(9): 1199 - 1209. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. Stuveling, S. J. L. Bakker, H. L. Hillege, P. E. de Jong, R. O. B. Gans, and D. de Zeeuw Biochemical risk markers: a novel area for better prediction of renal risk? Nephrol. Dial. Transplant., March 1, 2005; 20(3): 497 - 508. [Full Text] [PDF] |
||||
![]() |
E. O. Talbott, J. V. Zborowski, M. Y. Boudreaux, K. P. McHugh-Pemu, K. Sutton-Tyrrell, and D. S. Guzick The Relationship between C-Reactive Protein and Carotid Intima-Media Wall Thickness in Middle-Aged Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., December 1, 2004; 89(12): 6061 - 6067. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. B. Franz A Functional Biological Marker is Needed for Diagnosing Magnesium Deficiency J. Am. Coll. Nutr., December 1, 2004; 23(6): 738S - 741S. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. I. Sokol, E. L. Portnay, J. P. Curtis, M. A. Nelson, P. R. Hebert, J. F. Setaro, and J. M. Foody Modulation of the renin-angiotensin-aldosterone system for the secondary prevention of stroke Neurology, July 27, 2004; 63(2): 208 - 213. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. F Viles-Gonzalez, V. Fuster, and J. J Badimon Atherothrombosis: A widespread disease with unpredictable and life-threatening consequences Eur. Heart J., July 2, 2004; 25(14): 1197 - 1207. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Lombardo, L. M. Biasucci, G. A. Lanza, S. Coli, P. Silvestri, D. Cianflone, G. Liuzzo, F. Burzotta, F. Crea, and A. Maseri Inflammation as a Possible Link Between Coronary and Carotid Plaque Instability Circulation, June 29, 2004; 109(25): 3158 - 3163. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M Backes, P. A Howard, and P. M Moriarty Role of C-Reactive Protein in Cardiovascular Disease Ann. Pharmacother., January 1, 2004; 38(1): 110 - 118. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. J. Blake, N. Rifai, J. E. Buring, and P. M Ridker Blood Pressure, C-Reactive Protein, and Risk of Future Cardiovascular Events Circulation, December 16, 2003; 108(24): 2993 - 2999. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2003 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |